These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

816 related items for PubMed ID: 15102696

  • 1. Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and Its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma.
    Stein R, Qu Z, Chen S, Rosario A, Shi V, Hayes M, Horak ID, Hansen HJ, Goldenberg DM.
    Clin Cancer Res; 2004 Apr 15; 10(8):2868-78. PubMed ID: 15102696
    [Abstract] [Full Text] [Related]

  • 2. Epratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab.
    Carnahan J, Stein R, Qu Z, Hess K, Cesano A, Hansen HJ, Goldenberg DM.
    Mol Immunol; 2007 Feb 15; 44(6):1331-41. PubMed ID: 16814387
    [Abstract] [Full Text] [Related]

  • 3. Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties.
    Carnahan J, Wang P, Kendall R, Chen C, Hu S, Boone T, Juan T, Talvenheimo J, Montestruque S, Sun J, Elliott G, Thomas J, Ferbas J, Kern B, Briddell R, Leonard JP, Cesano A.
    Clin Cancer Res; 2003 Sep 01; 9(10 Pt 2):3982S-90S. PubMed ID: 14506197
    [Abstract] [Full Text] [Related]

  • 4. Bispecific anti-CD20/22 antibodies inhibit B-cell lymphoma proliferation by a unique mechanism of action.
    Qu Z, Goldenberg DM, Cardillo TM, Shi V, Hansen HJ, Chang CH.
    Blood; 2008 Feb 15; 111(4):2211-9. PubMed ID: 18025153
    [Abstract] [Full Text] [Related]

  • 5. Effects of specific anti-B and/or anti-plasma cell immunotherapy on antibody production in baboons: depletion of CD20- and CD22-positive B cells does not result in significantly decreased production of anti-alphaGal antibody.
    Alwayn IP, Xu Y, Basker M, Wu C, Buhler L, Lambrigts D, Treter S, Harper D, Kitamura H, Vitetta ES, Abraham S, Awwad M, White-Scharf ME, Sachs DH, Thall A, Cooper DK.
    Xenotransplantation; 2001 Aug 15; 8(3):157-71. PubMed ID: 11472623
    [Abstract] [Full Text] [Related]

  • 6. Epratuzumab: targeting B-cell malignancies through CD22.
    Coleman M, Goldenberg DM, Siegel AB, Ketas JC, Ashe M, Fiore JM, Leonard JP.
    Clin Cancer Res; 2003 Sep 01; 9(10 Pt 2):3991S-4S. PubMed ID: 14506198
    [Abstract] [Full Text] [Related]

  • 7. CD22-directed monoclonal antibody therapy for lymphoma.
    Siegel AB, Goldenberg DM, Cesano A, Coleman M, Leonard JP.
    Semin Oncol; 2003 Aug 01; 30(4):457-64. PubMed ID: 12939714
    [Abstract] [Full Text] [Related]

  • 8. Antilymphoma effects of anti-HLA-DR and CD20 monoclonal antibodies (Lym-1 and Rituximab) on human lymphoma cells.
    Liu C, DeNardo G, Tobin E, DeNardo S.
    Cancer Biother Radiopharm; 2004 Oct 01; 19(5):545-61. PubMed ID: 15650447
    [Abstract] [Full Text] [Related]

  • 9. Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma.
    Fanale MA, Younes A.
    Drugs; 2007 Oct 01; 67(3):333-50. PubMed ID: 17335294
    [Abstract] [Full Text] [Related]

  • 10. Enhanced efficacy of gemcitabine in combination with anti-CD20 monoclonal antibody against CD20+ non-Hodgkin's lymphoma cell lines in vitro and in scid mice.
    Smith MR, Joshi I, Jin F, Obasaju C.
    BMC Cancer; 2005 Aug 18; 5():103. PubMed ID: 16109167
    [Abstract] [Full Text] [Related]

  • 11. Characterization of a humanized IgG4 anti-HLA-DR monoclonal antibody that lacks effector cell functions but retains direct antilymphoma activity and increases the potency of rituximab.
    Stein R, Qu Z, Chen S, Solis D, Hansen HJ, Goldenberg DM.
    Blood; 2006 Oct 15; 108(8):2736-44. PubMed ID: 16778139
    [Abstract] [Full Text] [Related]

  • 12. Immunotherapy of non-Hodgkin's lymphoma with hLL2 (epratuzumab, an anti-CD22 monoclonal antibody) and Hu1D10 (apolizumab).
    Leonard JP, Link BK.
    Semin Oncol; 2002 Feb 15; 29(1 Suppl 2):81-6. PubMed ID: 11842393
    [Abstract] [Full Text] [Related]

  • 13. The evaluation of recombinant, chimeric, tetravalent antihuman CD22 antibodies.
    Meng R, Smallshaw JE, Pop LM, Yen M, Liu X, Le L, Ghetie MA, Vitetta ES, Ghetie V.
    Clin Cancer Res; 2004 Feb 15; 10(4):1274-81. PubMed ID: 14977825
    [Abstract] [Full Text] [Related]

  • 14. Use of ibritumomab tiuxetan anti-CD20 radioimmunotherapy in a non-Hodgkin's lymphoma patient previously treated with a yttrium-90-labeled anti-CD22 monoclonal antibody.
    Tsai DE, Maillard I, Schuster SJ, Nasta SD, Porter DL, Klumpp TR, Goldenberg DM, Luger SM, Alavi A, Sharkey RM, Hartzell KB, Stadtmauer EA.
    Clin Lymphoma; 2003 Jun 15; 4(1):56-9. PubMed ID: 12837157
    [Abstract] [Full Text] [Related]

  • 15. Anti-CD22/CD20 Bispecific antibody with enhanced trogocytosis for treatment of Lupus.
    Rossi EA, Chang CH, Goldenberg DM.
    PLoS One; 2014 Jun 15; 9(5):e98315. PubMed ID: 24841238
    [Abstract] [Full Text] [Related]

  • 16. Characterization of a novel humanized anti-CD20 antibody with potent anti-tumor activity against non-Hodgkin's lymphoma.
    Zhang H, Song L, Ye H, Hu L, Liang W, Liu D.
    Cell Physiol Biochem; 2013 Jun 15; 32(3):645-54. PubMed ID: 24022075
    [Abstract] [Full Text] [Related]

  • 17. Therapy of advanced B-lymphoma xenografts with a combination of 90Y-anti-CD22 IgG (epratuzumab) and unlabeled anti-CD20 IgG (veltuzumab).
    Mattes MJ, Sharkey RM, Karacay H, Czuczman MS, Goldenberg DM.
    Clin Cancer Res; 2008 Oct 01; 14(19):6154-60. PubMed ID: 18829494
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 41.